Assessment of growth and pain trajectories for children and adolescents receiving chemotherapy for acute lymphoblastic leukemia in Northern Thailand using group-based trajectory modeling - Scorecard - MDSpire
Advertisement
Assessment of growth and pain trajectories for children and adolescents receiving chemotherapy for acute lymphoblastic leukemia in Northern Thailand using group-based trajectory modeling
Clinical Scorecard: Evaluation of Growth Patterns and Pain Experiences in Pediatric Chemotherapy Patients with Acute Lymphoblastic Leukemia in Northern Thailand Utilizing Group-Based Trajectory Analysis
At a Glance
Category
Detail
Condition
Acute Lymphoblastic Leukemia (ALL)
Key Mechanisms
Growth changes and pain trajectories during chemotherapy
Target Population
Children and adolescents aged 1-15 years receiving chemotherapy for ALL
Care Setting
Pediatric oncology treatment
Key Highlights
Two-thirds of patients classified into slightly low-normal bodyweight group.
Older age at diagnosis associated with higher bodyweight and higher BMI.
High pain prevalence in 6-15-year-old patients.
94% of patients classified as healthy weight for BMI.
Thai ethnicity associated with mild pain trajectory.
Guideline-Based Recommendations
Diagnosis
Monitor growth changes and pain burden during ALL treatment.
Management
Implement proactive strategies to alleviate symptoms.
Monitoring & Follow-up
Assess bodyweight, BMI, and pain scores regularly during treatment.
Risks
Uncontrolled pain and inappropriate growth changes during chemotherapy.
Patient & Prescribing Data
Children and adolescents diagnosed with ALL aged 1-15 years.
Risk-adapted chemotherapy is the mainstay treatment for ALL.
Clinical Best Practices
Utilize Group-based Trajectory Modeling for assessing growth and pain trajectories.
Regularly evaluate pain using age-appropriate assessment tools.
